Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.48 |
| ▸ | BCHE | P06276 | 3/20 | 0.47 |
| ▸ | ACHE | P22303 | 3/20 | 0.47 |
| ▸ | BACE1 | P56817 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4046485 | 0.89 | MAPK1 (0.56) | SIGMAR1KMT2AMAPK1BCHEACHE | |
| SCHEMBL4049107 | 0.81 | SIGMAR1 (0.60) | SIGMAR1ALDH1A1POLBKMT2ABCHE | |
| SCHEMBL2101372 | 0.75 | POLB (0.42) | SIGMAR1POLBKMT2ARAB9A | |
| SCHEMBL5871316 | 0.72 | KDM4E (0.69) | SIGMAR1ALDH1A1POLBKMT2ABCHE | |
| SCHEMBL3288703 | 0.72 | MAPK1 (0.78) | SIGMAR1ALDH1A1POLBKMT2AMAPK1 | |
| SCHEMBL8035649 | 0.71 | SIGMAR1 (1.00) | SIGMAR1 | |
| SCHEMBL12677054 | 0.70 | KMT2A (1.00) | SIGMAR1ALDH1A1POLBKMT2ARAB9A | |
| SCHEMBL16225922 | 0.70 | ALDH1A1 (0.74) | SIGMAR1ALDH1A1KMT2A | |
| SCHEMBL8155639 | 0.70 | SIGMAR1 (0.63) | SIGMAR1ALDH1A1POLBKMT2ABCHE | |
| SCHEMBL16226357 | 0.69 | SLC6A3 (0.66) | SIGMAR1ALDH1A1BCHEACHEBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013214-B1 | CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2015-06-24 | — | — | EP | disclosed |
| US-7470680-B2 | Constrained compounds as CGRP-receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| US-20070259851-A1 | CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259851-A1 | CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS | CALCR, BDKRB2, CALCRL | SIGMAR1 907/4885ALDH1A1 3451/4885POLB 3259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.